U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07269210) titled 'A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia' on Nov. 26.
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Severe Hypertriglyceridemia
Intervention:
DRUG: Solbinsiran
Administered SC
DRUG: Placebo
Administered SC
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Published by HT Di...